Randomized double blind placebo controlled trial of the safety and efficacy of investigational herbal preparations for the treatment of patients with COVID-19

niversity of Peradeniya0 个研究点开始时间: 待定最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•1. Patients who understands and agrees to comply with planned study procedures.
•3. Patients who agree to the collection of nasopharyngeal swabs and venous blood per protocol.
•4. Male >18 years or non-pregnant female adult >18 years of age at the time of enrolement.
•5. Has a laboratory confirmed SARS-CoV-2 infection as determined by positive PCR done within 72 hrs, with a quantitative PCR cycle threshold (qPCR Ct value ) which is less than 25 and a positive Rapid antigen testing (RAT) performed at the point of admission.

•1. Known patients with chronic liver disease and kidney disease
•2. Alanine amino transferase (ALT) or Aspartate amino transferase (AST) or Serum creatinine> 2 times the upper limit of normal.
•3. Pregnancy or breast feeding.
•4. Anticipated transfer to another hospital which is not a study site within 72 hours.
•5. Allergy to any study medication
•6. Treatment with another investigational drug or other intervention
•7. Patients who are on warfarin, glucocorticoids and other immuno-suppressive medications or anti-cancer medications
•8. Patients with known substance abuse

发起方

niversity of Peradeniya